Clinical Trial Update: A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A single-arm Phase 2 trial evaluated pemetrexed as second-line therapy for advanced non-small cell lung cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small Cell Lung | Phase 2 | Status: COMPLETED